The National Cancer Institute, earlier this month, announced that it awarded a US $215,740 Small Business Innovation Research (SBIR) grant to support continued development of Igenica Biotherapeutics’ SNAP site-specific ADC linker technology.

SNAP technology, named for its speed and ease of use, overcomes the major limitations of current linker technologies by providing a simple, chemically-driven method for linking any anticancer antibody and small molecule cytotoxic drug to produce ADC products with optimal and uniform ratios of drug to antibody.

“Drug companies are aggressively pursuing ADCs as powerful new anti-cancer medicines comprised of a monoclonal antibody, a linker and a payload,” noted Mary Haak-Frendscho, Ph.D., chief executive officer of Igenica. “SNAP is a transformative, chemically-driven and broadly applicable technology that will accelerate the development of next-generation cancer therapeutics designed to selectively target cancer cells with potent cytotoxic agents. We are using this platform to strengthen our internal product pipeline and also will make it available to select partners.”

MabPlex
 

The current generation of ADCs, which are developed using conventional chemistry approaches, offer limited benefits to patients because they are heterogeneous drug mixtures containing variants with sub-optimal pharmaceutical properties. Igenica’s SNAP technology is comprised of a cutting-edge and proprietary linker that yields homogeneous ADCs armed with the optimal quantity of toxin payload to kill cancer cells. This approach should translate to drugs with lower toxicity and higher efficacy for cancer patients.

Published in: Igenica Biotherapeutics, Inc. website